Answers are grounded in this paper and cite their sources.
A disintegrin and metalloprotease 17 (ADAM17) is most known for the activation of pro TNF-α, but the functions of this sheddase extends to over 80 other cell surface proteins. Different levels of ADAM17 have been linked to inflammation and fibrosis in other diseases, but its role and the profile of its substrates in asthma is not known. Therefore, we aimed to assess the concentration of ADAM17 substrates in airway and blood samples of patients with asthma and healthy individuals. Bronchoalveolar lavage fluid (BALF) and plasma was collected from patients with asthma (n=11 and n=28 respectively) and healthy individuals (n=8 and n=25). Twentynine ADAM17 substrates were quantified in using the Luminex Multiplex Assay. Comparing asthma and healthy samples we found that Heparin-binding EGF-like growth factor (HB-EGF) was lower in the blood from asthma (p=0.010) indicating a reduced tissue repair mechanism. Syndecan-4 was also lower in the blood in asthma (p=0.010) but higher in BALF (p=0.035). That may be related to an increased directional migration of dendritic cells from the blood to the lungs. While IL-6R was higher in blood in asthma (p=0.001), that has previously been linked to increased asthma severity and diminished lung function. Although each of these substrates has been reported separately to effect different functions in the lungs and the progression of asthma, we believe it is important to assess the family of ADAM17 substrates as a cluster to gain a deeper understanding of how the ADAM17 family differs in asthma compared to healthy. Without assessing everything together we miss the combined effect that ADAM17 produces and its implications on asthma.
No takes yet. Share an insight, caveat, or question.
Larsson et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: